Every 8-K that NUO THERAPEUTICS INC NEW (AURX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AURX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AURX filings page.
Nuo Therapeutics, Inc. (AURX) closed the $325,000 Second Funding under its loan agreement on October 6, 2026, receiving the full amount. Aggregate funding received under the agreement is $2,000,000, matching the stated total commitment. The amendment set October 6 as the closing date and allowed a lender to assign $100,000 of its commitment; four lenders assumed equal $25,000 portions, including three new unaffiliated lenders and Scott M. Pittman, a director and more than 10% beneficial owner.
The notes bear 12% annual interest, payable in warrants, and mature December 31, 2028. For the assigned $100,000 commitment, the company issued warrants exercisable for 18,000 shares immediately and 1,832 shares subject to contingent vesting, and agreed to issue Interest Warrants for up to 11,000 shares at maturity or earlier voluntary or mandatory prepayment. For his additional $25,000 loan, Pittman received warrants for 4,500 immediately exercisable shares, 458 shares subject to contingent vesting, and up to 2,750 Interest Warrant shares. The amendment did not change other material loan terms or the warrants’ exercise price, expiration date, or other material economic terms.
Nuo Therapeutics, Inc. reported sharply higher revenue for the quarter ended June 30, 2026 and a smaller loss while updating on key commercial and financing developments. For the second quarter, total revenue was $1,768,986, up from $700,202 a year earlier, driven mainly by product sales growth. Gross profit increased to $1,170,027, and the quarterly net loss narrowed to $277,601 from $649,689, with loss per share steady at $0.01.
For the first half of 2026, revenue rose to $3,071,101 from $1,184,583, while the net loss improved to $896,067 from $1,395,817. The balance sheet shows total assets of $2,626,290 and total liabilities of $4,161,604, resulting in a stockholders’ deficit of $1,535,314. Management highlighted continued positive performance of the Smith+Nephew private label arrangement, confirmation of a reimbursement fee milestone expected to be paid this quarter, and an amended loan agreement providing additional working capital with an option to increase total borrowings on September 30, 2026 as the company works toward breakeven operations.
Nuo Therapeutics entered into an Amended and Restated Loan and Security Agreement providing up to $2.0 million in secured debt funding from five lenders. This includes $1,000,000 funded in January 2026, $675,000 funded on May 29, 2026, and up to $325,000 available on September 30, 2026, subject to conditions.
The notes bear 12% annual interest, payable in stock warrants rather than cash, and mature on December 31, 2028. Principal is interest-only through 2026 and then repaid quarterly in cash starting March 31, 2027. The debt is secured by liens on all company assets, including intellectual property, and must be prepaid upon certain equity financings, changes in control, or default, with prepayment fees paid in additional warrants.
In connection with the May 29 interim funding, Nuo issued multiple classes of warrants at a $1.50 exercise price, immediately exercisable for 120,125 shares, with additional tranches tied to potential second funding, prepayments, and accrued interest. Maximum Interest Warrants cover up to 303,667 shares for full utilization and repayment of the $2.0 million facility. Related-party lenders, including board member Scott Pittman and large shareholder Paul Jacobs, participated in both the loans and warrant issuances.
Nuo Therapeutics reported first quarter 2026 results showing higher sales and a smaller loss. Total revenue reached $1,302,115 for the three months ended March 31, 2026, up from $484,381 a year earlier, driven mainly by growth in Aurix product sales and new distribution fee revenue.
Net loss narrowed to $618,466 compared with $746,128 in the prior-year quarter, as gross profit increased while operating expenses also rose. As of March 31, 2026, Nuo reported cash of $263,827, total assets of $1,945,669, total liabilities of $3,329,532, and a stockholders’ deficit of $1,383,863.
Nuo Therapeutics, Inc. entered into a Loan and Security Agreement providing up to $1.6 million in secured term loans, with $1.0 million funded on January 23, 2026 and an additional $600 thousand available on September 30, 2026 if drawn. The loans bear interest at an annual rate of 10%, rising to 12% if the second tranche is funded, and mature on December 31, 2028, with principal repaid quarterly from March 31, 2027. The debt is secured by a lien on all company assets and includes mandatory prepayment upon certain equity financings, change in control events, or default, with prepayment fees paid in warrants instead of cash.
As part of this financing, Nuo issued multiple series of common stock warrants at a $1.50 exercise price, including fees, capital coverage, prepayment, and interest payment warrants, some of which vest only if the second tranche funds or if prepayment events occur. At closing the company issued warrants immediately exercisable for an aggregate of 148,000 shares and conditionally or potentially exercisable warrants for additional shares, including up to 226,000 shares in Interest Warrants tied to the full $1.6 million funding. Two significant shareholders, including director Scott M. Pittman, participated as lenders and received a portion of these warrants.
Nuo Therapeutics, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on December 16, 2025. Stockholders elected four directors to the board, ratified the company’s independent auditor, and approved executive compensation on an advisory basis.
Director nominees David E. Jorden, Paul D. Mintz, Scott M. Pittman, and C. Eric Winzer each received about 33.7 million votes in favor, with only a few thousand votes withheld and 2,237,142 broker non-votes. Stockholders ratified MaloneBailey LLP as independent registered public accounting firm with 35,917,807 votes for and 12,899 against, and approved the say-on-pay proposal with 33,653,458 votes for and 40,106 against, plus 2,237,142 broker non-votes.
Nuo Therapeutics, Inc. reported two governance actions: the board approved salary increases for its top executives and set the date for the 2025 Annual Meeting of Stockholders. Effective October 1, 2025, the salary for Chief Executive and Financial Officer David E. Jorden is $325,000 and the salary for Chief Scientific and Operating Officer Peter A. Clausen is $290,000. The board said the Committee considered an improvement in the company’s business and financial condition in 2025 when approving the increases.
The board fixed the Annual Meeting to be held at the company’s principal executive office on December 16, 2025. Stockholder proposals and director nominations for inclusion in the proxy materials must be received by the company’s Secretary by the close of business on October 20, 2025 and must comply with the company’s By-Laws and SEC rules.